FlowMedica推出BenephitDelta灌注系统

一种新型系统被设计用于将内科医生专用药物以及其它治疗药物直接给予肾功能不全患者的肾动脉之中，这些患者将从靶向肾脏治疗(TRT)中获益，包括那些充血性心衰的患者。这套系统已经获得了美国食品药品管理局的许可。

Benephit Delta系统是系统性静脉灌注给药系统标准给药方法的替代选择，用于治疗肾功能不全相关的心血管疾病、肾功能衰竭、以及充血性心衰。这套系统的早期版本局限在介入实验室中应用，将单个导管放入患者腹股沟股动脉入口处，进行介入手术进行靶向肾脏治疗。

Benephit Delta系统外观简练、灵活性增加、长度更长，从而能够进入诸如上肢这样的动脉位点。系统设计当患者接受治疗的时候具有更大机动性，当离开实验室的时候具有更好的舒适度。患者将从这种靶向肾脏治疗方法中获益，包括出现肾功能衰竭的慢性心衰患者以及急性肾功能衰竭患者。

Scripps诊所心血管科介入心脏病学主任Paul Teirstein医生评论说：“除了心-肾综合征的充血性心衰患者之外，Delta系统还能够用于治疗在重症监护室、手术中间或之后发生急性肾功能衰竭的患者。”

Benephit Delta系统是由FlowMedica公司研制开发成功的。

Infusion System for Kidney Patients
 
A new system is designed for the administration of physician-specified medications and other therapeutic agents directly into the renal arteries of patients with kidney dysfunction who may benefit from targeted renal therapy (TRT), including those with congestive heart failure. The system has been cleared by the U.S. Food and Drug Administration (FDA).

The Benephit Delta system is an alternative to the standard delivery method of systemic intravenous (IV) infusion of medications to treat kidney dysfunction related to cardiovascular disease, kidney failure, and congestive heart failure (CHF). An earlier version of the system was limited to use in the interventional laboratory, where a single catheter is placed in a femoral artery access site in the patient’s groin enabling interventional procedures to take place concurrently with TRT.

The reduced profile, increased flexibility, and longer lengths of the Benephit Delta system allow for access through arterial sites such as the arm. The system is designed to allow greater patient mobility and ease in providing therapy once the patient leaves the interventional laboratory. Patients who may benefit from this approach to TRT include CHF patients who develop kidney dysfunction and patients with acute renal failure.

“In addition to congestive heart failure patients who develop cardiorenal syndrome, the Delta system might also be used to provide therapy to patients who develop acute kidney failure while in the intensive care unit, during or after surgery,” commented Paul Teirstein, M.D., director of interventional cardiology, Division of Cardiovascular Diseases, Scripps Clinic (La Jolla, CA, USA).

The Benephit Delta system was developed by FlowMedica (Fremont, CA, USA).